Aaron Cranston Ph.D. Email & Phone Number

Delivered high quality preclinical candidate selection activities in a matrix team environment. Clinical positioning and biomarker development. Leading IHC activities for late-stage lead op projects and adopting machine learning and AI approaches for digital pathology and biomarker development. Evaluating new/novel approaches to improve translational predictions and clinical positioning. Site audits and establishing procedures for delivering quality systems for preclinical safety, tox and efficacy projects. Increased breadth, depth and access to preclinical partners. Established and developed good partner relations. Delivered high quality work packages to aid project positioning, inform the clinical path and achieved successful asset out-licensing.

Providing high quality oncology programmes in areas of unmet need. We are developing these with our partners and collaborators to deliver first-in-class and best-in-class therapies.

Belfast, Antrim, Gb

Cambridge, Cambs, Gb

Delivering highly innovative therapeutics targeting ubiquitin pathways to treat disease.Established MISSION's internal in vivo pharmacology capability from scratch. Delivered in vivo POC efficacy ahead of company milestones securing Series B funding.Led the internal and external preclinical pharmacology functions to progress novel agents into clinical development.Focussed on translational science activities across oncology & CNS therapeutic areas.

A client facing senior scientific project management role. Line management responsibility.Delivered preclinical models with improved predictability and improved quality to biotechs, academic institutions and major Pharma companies.Member of senior management team.

Offering project management (APM qualified) and preclinical scientific guidance for R&D projects.

Responsible for all in-life biology and bioanalytical deliverables for multiple concurrent projects with drug discovery and translational biology aspects. Most notably, led the in vivo pharmacology development of olaparib (Lynparza), a first-in-class PARP inhibitor approved for BRCA mutant advanced ovarian cancer.Legally responsible for all in-house pre-clinical work providing in vivo data to aid selection of compounds for clinical development.Coordinated biology, DMPK, safety & PAR&D activities and influenced translational science strategy for lead DDR inhibitors (DNA-PK, ATM, ATR and mTOR) which have now entered clinical trials.Seconded to AstraZeneca PK/PD/efficacy advisory board.

Built in-house in vivo pharmacology capability from scratch.Responsible for providing high quality data for five concurrent pre-clinical drug discovery & development projects to tight timelines.Project management of external CRO and academic collaborations.

Cambridge, England, Gb

Led MEN2 Cancer Group under auspices of Prof. Sir Bruce Ponder (Cambridge Institute for Medical Research) delivering on a CRC core funded project grant.Delivered biology projects using transgenic technologies to model human thyroid cancers in vivo; included intramural co-operation and forming a significant number of collaborations at leading international institutions.Identified and characterised new mutations; developed functional assays to advance medical genetics field and patient diagnosis/treatment; utilised network of national & international collaborations.Project management - supervised project direction & multiple lines of research.

Philadelphia, Pennsylvania, Us

NIH funded scholar exchange fellowship with Dr Richard Fishel.Biology projects modelling HNPCC using transgenic mouse models.Published extensively on mismatch repair, colon cancer and immunology.